| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $0 | — |
| R&D Expense | $8.0M | -3.1% |
| SG&A Expense | $202.3M | +34.8% |
| Operating Income | -$225.9M | -32.1% |
| Interest Expense | $170.0M | +94.2% |
| Income Tax | $0 | — |
| Net Income | -$429.6M | -254.9% |
| EPS (Basic) | -$1.17 | -387.5% |
| EPS (Diluted) | -$1.17 |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $143.8M | -2.9% |
| Current Assets | $718.0M | +74.0% |
| Total Assets | $12.43B | +94.0% |
| Current Liabilities | $1.34B | +124.5% |
| Long-term Debt | $8.83B | +118.8% |
| Total Liabilities | $10.12B | +117.3% |
| Stockholders' Equity | $95.3M | -74.8% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$169.4M | -77.2% |
| Capital Expenditures | $4.85B | +88.8% |
| Investing Cash Flow | -$4.85B | -88.5% |
| Financing Cash Flow | $5.34B | +92.8% |
| Free Cash Flow | -$5.02B | -88.3% |
| -387.5% |